Company Filing History:
1 out of 1 
1 out of 1 
1 out of 15 
Years Active: 2021-2024
Title: Mathias Vormehr: Innovator in Immunotherapy
Introduction
Mathias Vormehr is a prominent inventor based in Mainz, Germany. He has made significant contributions to the field of immunotherapy, particularly in the development of methods for predicting the usefulness of proteins and protein fragments. With a total of 2 patents, his work is paving the way for advancements in personalized cancer vaccines.
Latest Patents
Vormehr's latest patents focus on innovative methods for predicting peptides or polypeptides that are useful for immunotherapy. One of his inventions relates to predicting whether tumor-associated antigens or neoantigens are immunogenic and beneficial for vaccination. This method aims to provide vaccines that are tailored to a patient's specific tumor, enhancing the effectiveness of personalized cancer treatments. Another patent involves predicting T cell epitopes that are crucial for vaccination, emphasizing the importance of immunogenic modifications in peptides or polypeptides.
Career Highlights
Throughout his career, Mathias Vormehr has worked with notable companies such as BioNTech RNA Pharmaceuticals GmbH and TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz. His experience in these organizations has allowed him to collaborate on groundbreaking research in the field of cancer immunotherapy.
Collaborations
Vormehr has had the opportunity to work alongside esteemed colleagues, including Ugur Sahin and Martin Löwer. Their combined expertise has contributed to the advancement of innovative solutions in cancer treatment.
Conclusion
Mathias Vormehr's contributions to immunotherapy through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in personalized medicine and cancer treatment.